Skip to content
- Halimi JM, et al. Effets vasculaires et rénaux des médicaments antiangiogéniques : recommandations françaises pour la pratique. Sang Thromb Vaiss 2009;21:151-66.
- Izzedine H, et al. Interstitial nephritis in a patient taking sorafenib. Nephrol Dial Transplant 2007;22:2411.
- Izzedine H, et al. Thrombotic microangiopathy and anti-VEGF agents. Nephrol Dial Transplant 2007;22:1481-2.
- Izzedine H, et al. VEGF signalling inhibition-induced proteinuria: mechanisms, significance and management. Eur J Cancer 2010;46(2):439-48.
- Zhu X, et al. Risks of proteinuria and hypertension with bevacizumab, an antibody against vascular endothelial growth factor: systematic review and meta-analysis. Am J Kidney Dis 2007;49:186-93.
- Vigneau C, et al. Renal toxicity of anti-VEGF (corrected) targeted therapies. Nephrol Ther 2013;9(3):174-9.
- Eisen T, et al. Targeted therapies for renal cell carcinoma: review of adverse event management strategies. J Natl Cancer Inst 2012;104(2):93-113.
- Dasanu CA, et al. Cardiovascular toxicity associated with small molecule tyrosine kinase inhibitors currently in clinical use. Expert Opin Drug Saf 2012;11(3):445-57.
- Qi WX, et al. Incidence and risk of hypertension with vandetanib in cancer patients: a systematic review and meta-analysis of clinical trials. Br J Clin Pharmacol 2013;75(4):919-30.
- De Wit M; et al. Prevention and management of adverse events related to regorafenib. Support Care Cancer 2014;22(3):837-46.
- Société Française d’Hypertension Artérielle – www.sfhta.org (dernière consultation en janvier 2014).